Opinion|Videos|December 12, 2024
Dosing Trifluridine-Tipiracil (TAS-102) Plus Bevacizumab Considerations: Hepatic or Renal Impairment
Panelists discuss the frequency of hypertension observed with trifluridine-tipiracil plus bevacizumab and their strategies for monitoring and managing it, as well as their approach to dosing TAS-102 plus bevacizumab in patients with hepatic or renal impairment. They also review common toxicities associated with fruquintinib and regorafenib, including hypertension, hand-foot syndrome, and hepatotoxicity, and share management strategies for these adverse events.
Advertisement
Episodes in this series
- How frequently are you observing hypertension when treating your patients with trifluridine-tipiracil plus bevacizumab? What is your monitoring and management strategy for hypertension?
- How often do you see patients with hepatic or renal impairment in your clinical practice? What is your dosing strategy for TAS-102 plus bevacizumab for those who have hepatic or renal impairment?
- What are some common toxicities associated with fruquintinib? How do you manage patients who may develop hypertension, hand-foot syndrome, or hepatotoxicity?
- What are some common toxicities associated with regorafenib? How does your clinic manage potential toxicities seen with regorafenib, like hand-foot syndrome?
Advertisement
Related to this article
The final OS analysis of PAPILLON did not reach statistical significance in the ITT population, but a pre-specified crossover-adjusted analysis showed a 43% reduction in the risk of death.
An exploratory landmark analysis of the phase 3 ADAURA trial showed 8-year OS rates of 79% versuss 64% with placebo, with benefit maintained across stages and subgroups.
Frontline zidesamtinib produced a 94% response rate and 100% intracranial response rate in TKI-naive ROS1-positive advanced NSCLC.
First-line trastuzumab deruxtecan reduced the risk of progression or death by 37% compared with pembrolizumab plus chemotherapy in HER2-mutant non–small cell lung cancer.
Edgardo S. Santos Castillero, MD, discusses MAVERICK, B7-H3 ADC data, and tarlatamab sequencing in SCLC, plus molecular testing in a value-based practice.
Adding intercalated gefitinib to adjuvant chemotherapy improved DFS vs chemotherapy alone in completely resected stage II-IIIB EGFR-mutant NSCLC in a phase 3 trial.
The top 5 OncLive TV videos of the week cover insights in polycythemia vera, myelodysplastic syndrome, myelofibrosis, and acute myeloid leukemia.
A real-world study found just one-third of patients remained on adjuvant osimertinib at 3 years, with early discontinuation linked to worse disease-free survival.
Advertisement
Advertisement
Trending on OncLive
1
Ris-Rez Extends Median OS to 18.5 Months vs Topotecan in Relapsed SCLC
2
Tam-Peli Reduces Risk of Death by 54% vs Topotecan in Relapsed SCLC
3
Early Discontinuation of Adjuvant Osimertinib Doubles Recurrence Risk in EGFR-Mutated NSCLC
4
DESTINY-Lung04 Showcases PFS Benefit With First-Line T-DXd in HER2-Mutant NSCLC
5